AUAUniversity Podcast Series: Episode No. 26
Sequencing Of Agents And Combination Therapy In Castrate Resistant Prostate Cancer
Co-Host: Maxwell Meng, MD
At the conclusion of these activities, participants will be able to:
1. Identify treatments for non-metastatic and metastatic CRPC and describe the proper order for their administration.
2. Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy.
3. Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC.
This educational series is supported by independent educational grants from:
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb
Genomic Health
Merck
Pfizer, Inc.
Sanofi Genzyme
UroGen Pharma